Myeloperoxidase–Antineutrophil Cytoplasmic Antibody (ANCA)–Positive and ANCA-Negative Patients With Granulomatosis With Polyangiitis (Wegener's): Distinct Patient Subsets

Arthritis and Rheumatology

Volumn 68, Issue 12, 2016, Pages 2945-2952

  Miloslavsky, Eli M ^a   Lu, Na ^a   Unizony, Sebastian ^a   Choi, Hyon K ^a   Merkel, Peter A ^b   Seo, Philip ^c   Spiera, Robert ^d   Langford, Carol A ^e   Hoffman, Gary S ^e   Kallenberg, Cees G M ^f   St Clair, E William ^g   Tchao, Nadia K ^h   Fervenza, Fernando ⁱ   Monach, Paul A ^j   Specks, Ulrich ⁱ   Stone, John H ^a  

^a MASSACHUSETTS GENERAL HOSPITAL   (United States)

^b UNIVERSITY OF PENNSYLVANIA   (United States)

^c JOHNS HOPKINS UNIVERSITY   (United States)

^d HOSPITAL FOR SPECIAL SURGERY   (United States)

^e LERNER RESEARCH INSTITUTE   (United States)

^f UNIVERSITY OF GRONINGEN   (Netherlands)

^g DUKE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^h Immune Tolerance Network   (United States)

ⁱ MAYO CLINIC   (United States)

^j BOSTON UNIVERSITY   (United States)

more..

Author keywords

[No Author keywords available]

Indexed keywords

AZATHIOPRINE; CYCLOPHOSPHAMIDE; ETANERCEPT; GLUCOCORTICOID; METHOTREXATE; MYELOPEROXIDASE; NEUTROPHIL CYTOPLASMIC ANTIBODY; PLACEBO; PREDNISONE; RITUXIMAB; ANTIRHEUMATIC AGENT; MYELOBLASTIN; PEROXIDASE;

ADULT; ANCA ASSOCIATED VASCULITIS; ARTICLE; BIRMINGHAM VASCULITIS ACTIVITY SCORE; CLINICAL OUTCOME; CONTROLLED STUDY; DRUG DOSE REDUCTION; DRUG WITHDRAWAL; FEMALE; GROUPS BY AGE; HUMAN; KIDNEY FAILURE; MAJOR CLINICAL STUDY; MALE; MIDDLE AGED; PREVALENCE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); RECURRENCE RISK; RELAPSE; SCORING SYSTEM; WEGENER GRANULOMATOSIS; COMPLICATION; EYE DISEASES; GRANULOMATOSIS WITH POLYANGIITIS; IMMUNOLOGY; KIDNEY DISEASES; LUNG DISEASES; NERVOUS SYSTEM DISEASES; OTORHINOLARYNGOLOGIC DISEASES; PATHOPHYSIOLOGY; RECURRENT DISEASE; SEVERITY OF ILLNESS INDEX;

ANTIBODIES, ANTINEUTROPHIL CYTOPLASMIC; ANTIRHEUMATIC AGENTS; ETANERCEPT; EYE DISEASES; FEMALE; GRANULOMATOSIS WITH POLYANGIITIS; HUMANS; KIDNEY DISEASES; LUNG DISEASES; MALE; MIDDLE AGED; MYELOBLASTIN; NERVOUS SYSTEM DISEASES; OTORHINOLARYNGOLOGIC DISEASES; PEROXIDASE; RECURRENCE; RITUXIMAB; SEVERITY OF ILLNESS INDEX;

EID: 84997610337     PISSN: 23265191     EISSN: 23265205     Source Type: Journal    
DOI: 10.1002/art.39812     Document Type: Article

References (30)

1. Lyons PA, Rayner TF, Trivedi S, Holle JU, Watts RA, Jayne DR, et al. Genetically distinct subsets within ANCA-associated vasculitis. N Engl J Med 2012;367:214–23.
2. Mahr A, Katsahian S, Varet H, Guillevin L, Hagen EC, Hoglund P, et al. Revisiting the classification of clinical phenotypes of anti-neutrophil cytoplasmic antibody-associated vasculitis: a cluster analysis. Ann Rheum Dis 2013;72:1003–10.
3. Lionaki S, Blyth ER, Hogan SL, Hu Y, Senior BA, Jennette CE, et al. Classification of antineutrophil cytoplasmic autoantibody vasculitides: the role of antineutrophil cytoplasmic autoantibody specificity for myeloperoxidase or proteinase 3 in disease recognition and prognosis. Arthritis Rheum 2012;64:3452–62.
4. Hoffman GS, Kerr GS, Leavitt RY, Hallahan CW, Lebovics RS, Travis WD, et al. Wegener granulomatosis: an analysis of 158 patients. Ann Intern Med 1992;116:488–98.
5. Finkielman JD, Lee AS, Hummel AM, Viss MA, Jacob GL, Homburger HA, et al. ANCA are detectable in nearly all patients with active severe Wegener's granulomatosis. Am J Med 2007;120:643.e9–14.
6. Schonermarck U, Lamprecht P, Csernok E, Gross WL. Prevalence and spectrum of rheumatic diseases associated with proteinase 3-antineutrophil cytoplasmic antibodies (ANCA) and myeloperoxidase-ANCA. Rheumatology (Oxford) 2001;40:178–84.
7. Ikeda S, Arita M, Misaki K, Kashiwagi Y, Ito Y, Yamada H, et al. Comparative investigation of respiratory tract involvement in granulomatosis with polyangiitis between PR3-ANCA positive and MPO-ANCA positive cases: a retrospective cohort study. BMC Pulm Med 2015;15:78.
8. Ono N, Niiro H, Ueda A, Sawabe T, Nishizaka H, Furugo I, et al. Characteristics of MPO-ANCA-positive granulomatosis with polyangiitis: a retrospective multi-center study in Japan. Rheumatol Int 2015;35:555–9.
9. Tsuchida Y, Shibuya M, Shoda H, Sumitomo S, Kubo K, Setoguchi K, et al. Characteristics of granulomatosis with polyangiitis patients in Japan. Mod Rheumatol 2015;25:219–23.
10. Wegener's Granulomatosis Etanercept Trial (WGET) Research Group. Etanercept plus standard therapy for Wegener's granulomatosis. N Engl J Med 2005;352:351–61.
11. Stone JH, Merkel PA, Spiera R, Seo P, Langford CA, Hoffman GS, et al. Rituximab versus cyclophosphamide for ANCA-associated vasculitis. N Engl J Med 2010;363:221–32.
12. Specks U, Merkel PA, Hoffman GS, Langford CA, Spiera R, Seo P, et al. Design of the rituximab in ANCA-Associated Vasculitis (RAVE) trial. Open Arthritis J 2011;4:1–18.
13. Leavitt RY, Fauci AS, Bloch DA, Michel BA, Hunder GG, Arend WP, et al. The American College of Rheumatology 1990 criteria for the classification of Wegener's granulomatosis. Arthritis Rheum 1990;33:1101–7.
14. Miloslavsky EM, Specks U, Merkel PA, Seo P, Spiera R, Langford CA, et al. Outcomes of nonsevere relapses in antineutrophil cytoplasmic antibody–associated vasculitis treated with glucocorticoids. Arthritis Rheumatol 2015;67:1629–36.
15. Jennette JC, Falk RJ, Andrassy K, Bacon PA, Churg J, Gross WL, et al. Nomenclature of systemic vasculitides: proposal of an international consensus conference. Arthritis Rheum 1994;37:187–92.
16. Wiesner O, Russell KA, Lee AS, Jenne DE, Trimarchi M, Gregorini G, et al. Antineutrophil cytoplasmic antibodies reacting with human neutrophil elastase as a diagnostic marker for cocaine-induced midline destructive lesions but not autoimmune vasculitis. Arthritis Rheum 2004;50:2954–65.
17. Stone JH, Hoffman GS, Merkel PA, Min YI, Uhlfelder ML, Hellmann DB, et al. for the International Network for the Study of the Systemic Vasculitides (INSSYS). A disease-specific activity index for Wegener's granulomatosis: modification of the Birmingham Vasculitis Activity Score. Arthritis Rheum 2001;44:912–20.
18. Exley AR, Bacon PA, Luqmani RA, Kitas GD, Gordon C, Savage CO, et al. Development and initial validation of the Vasculitis Damage Index for the standardized clinical assessment of damage in the systemic vasculitides. Arthritis Rheum 1997;40:371–80.
19. Jennette JC, Falk RJ, Bacon PA, Basu N, Cid MC, Ferrario F, et al. 2012 revised International Chapel Hill Consensus Conference Nomenclature of Vasculitides. Arthritis Rheum 2013;65:1–11.
20. WGET Research Group. Design of the Wegener's Granulomatosis Etanercept Trial (WGET). Control Clin Trials 2002;23:450–68.
21. Millet A, Pederzoli-Ribeil M, Guillevin L, Witko-Sarsat V, Mouthon L. Antineutrophil cytoplasmic antibody-associated vasculitides: is it time to split up the group? Ann Rheum Dis 2013;72:1273–9.
22. Finkielman JD, Merkel PA, Schroeder D, Hoffman GS, Spiera R, St Clair EW, et al. Antiproteinase 3 antineutrophil cytoplasmic antibodies and disease activity in Wegener granulomatosis. Ann Intern Med 2007;147:611–9.
23. Wegener's Granulomatosis Etanercept Trial Research Group. Limited versus severe Wegener's granulomatosis: baseline data on patients in the Wegener's Granulomatosis Etanercept Trial. Arthritis Rheum 2003;48:2299–309.
24. Mohammad AJ, Jacobsson LT, Mahr AD, Sturfelt G, Segelmark M. Prevalence of Wegener's granulomatosis, microscopic polyangiitis, polyarteritis nodosa and Churg-Strauss syndrome within a defined population in southern Sweden. Rheumatology (Oxford) 2007;46:1329–37.
25. Mahr A, Guillevin L, Poissonnet M, Ayme S. Prevalences of polyarteritis nodosa, microscopic polyangiitis, Wegener's granulomatosis, and Churg-Strauss syndrome in a French urban multiethnic population in 2000: a capture-recapture estimate. Arthritis Rheum 2004;51:92–9.
26. Guillevin L, Durand-Gasselin B, Cevallos R, Gayraud M, Lhote F, Callard P, et al. Microscopic polyangiitis: clinical and laboratory findings in eighty-five patients. Arthritis Rheum 1999;42:421–30.
27. Fujimoto S, Watts RA, Kobayashi S, Suzuki K, Jayne DR, Scott DG, et al. Comparison of the epidemiology of anti-neutrophil cytoplasmic antibody-associated vasculitis between Japan and the U.K. Rheumatology (Oxford) 2011;50:1916–20.
28. Hoang LT, Lim LL, Vaillant B, Choi D, Rosenbaum JT. Antineutrophil cytoplasmic antibody-associated active scleritis. Arch Ophthalmol 2008;126:651–5.
29. Nolle B, Specks U, Ludemann J, Rohrbach MS, DeRemee RA, Gross WL. Anticytoplasmic autoantibodies: their immunodiagnostic value in Wegener granulomatosis. Ann Intern Med 1989;111:28–40.
30. Pagnoux C, Carette S, Khalidi NA, Walsh M, Hiemstra TF, Cuthbertson D, et al. Comparability of patients with ANCA-associated vasculitis enrolled in clinical trials or in observational cohorts. Clin Exp Rheumatol 2015;33 Suppl 89:S77–83.